Agomab Therapeutics vs Eikon Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Nasdaq IPO Feb 2026 (~$200M raised, ~$780M valuation, ticker AGMB). Positive Phase 2a data for ontunisertib in fibrostenosing Crohn's. Phase 1 data for AGMB-447 in IPF. Gut-restricted ALK5 inhibitor.
About
Agomab Therapeutics went public on Nasdaq in February 2026, raising approximately $200 million at an ~$780 million valuation (ticker: AGMB), becoming one of the first European biotechs to list in the US in 2026. Agomab is developing ontunisertib — the only clinical-stage gut-restricted ALK5/TGFβR1 inhibitor for fibrostenosing Crohn's disease, a severe complication where intestinal fibrosis causes strictures requiring repeated surgery. The company also has AGMB-447 in Phase 1 for idiopathic pulmonary fibrosis (IPF), using lung-restricted delivery of the same mechanism.
Raised $381M IPO on Nasdaq (Feb 2026, EIKN). Proprietary RESOLFT super-resolution microscopy tracks single protein molecules in living cells. Creates new drug discovery data category.
About
Eikon Therapeutics is a drug discovery company that went public on Nasdaq in February 2026 (ticker: EIKN) with a $381 million IPO, armed with a proprietary RESOLFT super-resolution microscopy platform that tracks individual protein molecules in living cells in real time. Unlike computational drug discovery approaches that model proteins in isolation, Eikon's platform observes how proteins actually behave within the complex, dynamic environment of living cells — generating a new category of drug discovery data that no other method can produce.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.